INS and diabetic cardiomyopathy: Improvement of metabolic abnormalities and impaired glucose tolerance, including lowering blood glucose and insulin levels and reducing body weight and heart weight,and protection against diabetic cardiomyopathy by activating the FXR-mediated Nrf2 signaling pathway